PRKAA1 and type 2 diabetes mellitus: Metformin, an anti-hyperglycemic drug used to treat Type II Diabetes Mellitus, is best known as an indirect activator of AMPK, although it can also mediate multiple non-AMPK-dependent effects (Foretz et al., 2014).